All the Latest News

News_BG1

Author: Iceni Pharma


Homepage_BG1

Iceni Pharmaceuticals launches as new company focusing on repurposing therapies in the field of oncology

25th May 2016, EDINBURGH, UK – Iceni Pharmaceuticals announces its launch as a new company, focusing on developing repurposed and reformulated cancer therapies. The company’s lead product Cilcane® (generic name cilengitide) …

Read more
Iceni_News_01

Iceni Pharmaceuticals announces appointment of cilengitide inventor Prof. Dr. Horst Kessler to its Scientific Advisory Board

Edinburgh, UK. 2 April 2016. Iceni Pharmacuticals, an oncology drug development company announced today that Prof Dr Horst Kessler has joined its Scientific Advisory Board.
Read more
Iceni_News

Iceni Pharmaceuticals parent company BigDNA Ltd announces completion of internal funding round

Edinburgh, UK. 1 March 2016. BigDNA Ltd, parent organisation of oncology drug development company Iceni Pharmaceuticals announced today that it has completed a £0.5M investment round from internal shareholders, including London-based Imprimatur Capital and the Scottish Investment Bank.
Read more
Loading